Projects overview

Sort by


Toggle all information

theEoE | A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

01-12-2016

-

30-04-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

EASIVIRAL | EASIVIRAL

01-12-2017

-

30-11-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

DualDur | DualDur: A Disruptive Diagnostic Technology that Enables for the First Time an Early and Accurate Diagnosis of the tick-borne Lyme Disease.

01-04-2018

-

30-06-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

Sencell16 | Lifecare’s Sencell sensor is an implantable micro-sensor for subcutaneous location, long time, continuous, wireless, real time monitoring of interstitial glucose for diabetes management.

01-08-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

FGFSTAB | Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

01-03-2017

-

28-02-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

HEXKIN | Healing Exosomes for sKIN

01-12-2016

-

31-03-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

NANO-GROWTH | An innovative, non-invasive and de-risked system to enable the transdermal delivery of fragile therapeutic compounds for a better management of painful diseases

01-02-2017

-

31-05-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

SULIPRO | A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need

01-02-2017

-

31-05-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

BloodStemPLUS | Commercial feasibility study of a technology that multiplies blood stem cells to increase the success of transplants for cancer treatment

01-06-2016

-

30-09-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

RAM | RAM is a revolutionary magneto-optical technology platform, outperforming current solutions in accuracy, cost, and time to diagnosis, when assessing human blood cells for Malaria presence

01-10-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

Fucoderm | An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

01-12-2016

-

31-03-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

DeCISIoN | Drug CandIdates ScreenINg

01-07-2016

-

31-12-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

CardAPcells | Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart”

01-07-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

BriScrew | BioResorbable Ostheosynthesis Implant

01-03-2017

-

30-06-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

POLYBOOST | POLYBOOST: Renovating the Polyclonal Immunotherapy

01-12-2016

-

31-03-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

ABD | A bioengineered, naturally-derived, sustainable biocide for breaking down organic biofilms formed by drug-resistant bacteria.

01-12-2016

-

30-04-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

METAdiag | METAdiag: Diagnose to Cure

01-02-2017

-

31-05-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

HoloCyt | A rapid, low-cost, cervical cancer screening platform

01-01-2017

-

30-06-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

AGLARIS | AGLARIS: The First Fully-automated Bioreactor for Large Scale Human Stem Cell Production through an Iterative Process.

01-06-2016

-

30-09-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

tagMDR | Identification of Multidrug Resistance for Chemotherapy Guidance in Cancer Using a Lab-on-a-chip Platform

01-08-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
Powered by Chris Decubber BV